Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
1.970
-0.060 (-2.96%)
At close: Dec 5, 2025, 4:00 PM EST
2.050
+0.080 (4.06%)
After-hours: Dec 5, 2025, 6:06 PM EST
Lisata Therapeutics Revenue
Lisata Therapeutics had revenue of $1.07M in the twelve months ending September 30, 2025. In the year 2024, Lisata Therapeutics had annual revenue of $1.00M.
Revenue (ttm)
$1.07M
Revenue Growth
n/a
P/S Ratio
15.81
Revenue / Employee
$41,154
Employees
26
Market Cap
17.38M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LSTA News
- 4 weeks ago - Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year' - GlobeNewsWire
- 4 weeks ago - Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - GlobeNewsWire
- 5 weeks ago - Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - GlobeNewsWire
- 7 weeks ago - Lisata Therapeutics to Present at LD Micro Main Event XIX - Newsfile Corp
- 2 months ago - Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement - GlobeNewsWire
- 2 months ago - Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial - GlobeNewsWire